VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 2, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that enrolment is complete in the Phase II clinical trial evaluating Allon's drug candidate AL-108 as a treatment for Alzheimer's disease. This trial has progressed ahead of schedule and is expected to be the first of Allon's three Phase II efficacy trials to report top line data, with results expected in Q1 2008.
